{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Ovarian+Cancer",
    "query": {
      "condition": "Advanced Ovarian Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 706,
    "total_pages": 71,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Ovarian+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T07:27:50.195Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03761914",
      "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Ovarian Cancer",
        "Colorectal Cancer",
        "Triple-negative Breast Cancer",
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "galinpepimut-S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide",
          "type": "OTHER"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sellas Life Sciences Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-09-30",
      "completion_date": "2022-10-27",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Whittier, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761914"
    },
    {
      "nct_id": "NCT03507452",
      "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma",
        "Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma",
        "Advanced Recurrent Serous Ovarian Cancer",
        "Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)"
      ],
      "interventions": [
        {
          "name": "BAY2287411",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2018-06-13",
      "completion_date": "2022-03-29",
      "has_results": false,
      "last_update_posted_date": "2023-03-20",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03507452"
    },
    {
      "nct_id": "NCT06546553",
      "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Non-small-cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07826390",
          "type": "DRUG"
        },
        {
          "name": "sasanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SOC (anti-PD-1 + platinum -based chemo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-09-06",
      "completion_date": "2025-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546553"
    },
    {
      "nct_id": "NCT03239145",
      "title": "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trebananib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2018-05-01",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03239145"
    },
    {
      "nct_id": "NCT04502602",
      "title": "Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Neratinib 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Neratinib 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Neratinib 240 mg",
          "type": "DRUG"
        },
        {
          "name": "Niraparib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Niraparib 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Niraparib 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Niraparib at RP2D",
          "type": "DRUG"
        },
        {
          "name": "Neratinib at RP2D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2020-08-24",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04502602"
    },
    {
      "nct_id": "NCT03957096",
      "title": "A Safety Study of SGN-CD47M in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Soft Tissue Sarcoma",
        "Colorectal Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Breast Carcinoma",
        "Ovarian Carcinoma",
        "Exocrine Pancreatic Carcinoma",
        "Gastric Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "SGN-CD47M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-07-17",
      "completion_date": "2020-09-14",
      "has_results": false,
      "last_update_posted_date": "2020-09-17",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 5,
      "location_summary": "Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03957096"
    },
    {
      "nct_id": "NCT06840886",
      "title": "A Study of PHST001 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Cholangiocarcinoma",
        "CNS Tumor"
      ],
      "interventions": [
        {
          "name": "PHST001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy per Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Pheast Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2025-03-31",
      "completion_date": "2031-04",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 20,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06840886"
    },
    {
      "nct_id": "NCT04803305",
      "title": "Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Colorectal Cancer",
        "Prostate Cancer",
        "Breast Cancer",
        "Ovarian Cancer",
        "Loss of Appetite",
        "Fatigue",
        "Cachexia",
        "Anorexia"
      ],
      "interventions": [
        {
          "name": "PF-06946860",
          "type": "DRUG"
        },
        {
          "name": "Placebo for PF-06946860",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-05-11",
      "completion_date": "2022-08-09",
      "has_results": true,
      "last_update_posted_date": "2024-01-12",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 32,
      "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Camarillo",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04803305"
    },
    {
      "nct_id": "NCT00005807",
      "title": "Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "BMS-247550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2000-07",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 2,
      "location_summary": "New York, New York • The Bronx, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005807"
    },
    {
      "nct_id": "NCT00245102",
      "title": "Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Angiosarcoma",
        "Adult Epithelioid Sarcoma",
        "Adult Leiomyosarcoma",
        "Adult Malignant Fibrous Histiocytoma",
        "Adult Neurofibrosarcoma",
        "Adult Synovial Sarcoma",
        "Ovarian Sarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Uterine Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage III Uterine Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Stage IV Uterine Sarcoma",
        "Uterine Carcinosarcoma",
        "Uterine Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2005-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2014-05-23",
      "last_synced_at": "2026-06-10T07:27:50.195Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245102"
    }
  ]
}